Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.27, for a total value of $2,445,400.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at $23,758,161.43. This represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00.

Mirum Pharmaceuticals Trading Up 0.2%

NASDAQ:MIRM opened at $128.57 on Thursday. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $129.00. The business’s 50-day moving average price is $105.26 and its two-hundred day moving average price is $97.20. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $7.84 billion, a price-to-earnings ratio of -9.45 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on MIRM shares. JPMorgan Chase & Co. upped their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. CLSA set a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Evercore restated an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $143.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Glenmede Trust Co. NA increased its position in shares of Mirum Pharmaceuticals by 66.9% during the first quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock worth $511,000 after acquiring an additional 2,217 shares in the last quarter. Janus Henderson Group PLC lifted its position in Mirum Pharmaceuticals by 14.5% in the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Mirum Pharmaceuticals in the 1st quarter worth $573,000. California State Teachers Retirement System boosted its stake in Mirum Pharmaceuticals by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 44,476 shares of the company’s stock worth $4,109,000 after purchasing an additional 8,065 shares during the period. Finally, Rock Springs Capital Management LP increased its holdings in Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock worth $74,947,000 after purchasing an additional 49,000 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.